GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia

References

• Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977;63:125–130.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988;319:990–998.
   PubMed Web of Science ®Google Scholar
• Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277–280.
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079.
   PubMed Web of Science ®Google Scholar
• Bj D, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: A therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013;13:1433–1452.
   PubMed Web of Science ®Google Scholar
• Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for chronic myelogenous leukemia. Cancer J. 2011;17:477–486.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018–1029.
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011;25:7–22.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321–1331.
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004;64:672.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia. 2006;20:658–663.
   PubMed Web of Science ®Google Scholar
• Ma L, Shan Y, Bai R, et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014;6:252ra121.
   PubMed Web of Science ®Google Scholar
• Yorimitsu T, Klionsky DJ. Autophagy: molecular machinery for self-eating. Cell Death Differ. 2005;12:1542–1552.
   PubMed Web of Science ®Google Scholar
• Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132–141.
   PubMed Web of Science ®Google Scholar
• Nazio F, Strappazzon F, Antonioli M, et al. mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6. Nat Cell Biol. 2013;15:406–416.
   PubMed Web of Science ®Google Scholar
• Ertmer A, Huber V, Gilch S, et al. The anticancer drug imatinib induces cellular autophagy. Leukemia. 2007;21:936.
   PubMed Web of Science ®Google Scholar
• Sheng Z, Ma LY, Sun JYE, et al. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood. 2011;118:2840–2848.
   PubMed Web of Science ®Google Scholar
• Sehgal AR, Konig H, Johnson DE, et al. You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia. 2015;29:517–525.
   PubMed Web of Science ®Google Scholar
• Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood. 2011;118:2035.
   PubMed Web of Science ®Google Scholar
• Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009;119:1109–1123.
   PubMed Web of Science ®Google Scholar
• Karvela M, Baquero P, Kuntz EM, et al. ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. Autophagy. 2016;12:936–948.
   PubMed Web of Science ®Google Scholar
• Boyhan A, Casimir CM, French JK, et al. Molecular cloning and characterization of grancalcin, a novel EF-hand calcium-binding protein abundant in neutrophils and monocytes. J Biol Chem. 1992;267:2928–2933.
   PubMed Web of Science ®Google Scholar
• Teahan CG, Totty NF, Segal AW. Isolation and characterization of grancalcin, a novel 28 kDa EF-hand calcium-binding protein from human neutrophils. Biochem J. 1992;286(Pt 2):549–554.
   PubMedGoogle Scholar
• Maki M, Narayana SV, Hitomi K. A growing family of the Ca2+-binding proteins with five EF-hand motifs. Biochem J. 1997;328(Pt 2):718–720.
   PubMedGoogle Scholar
• Kim TW, Hong S, Talukder AH, et al. Grancalcin (GCA) modulates Toll-like receptor 9 (TLR9) mediated signaling through its direct interaction with TLR9. Eur J Immunol. 2016;46:712–724.
   PubMed Web of Science ®Google Scholar
• Roes J, Choi BK, Power D, et al. Granulocyte function in grancalcin-deficient mice. Mol Cell Biol. 2003;23:826–830.
   PubMed Web of Science ®Google Scholar
• Kim TM, Ha SA, Kim HK, et al. Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib. Blood Cancer J. 2011;1:e32.
   PubMed Web of Science ®Google Scholar
• Wolf A, Couttet P, Dong M, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res. 2010;34:1180–1188.
   PubMed Web of Science ®Google Scholar
• Tazzari M, Indio V, Vergani B, et al. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. J Invest Dermatol. 2017;137:484–493.
   PubMed Web of Science ®Google Scholar
• Atwell S, Adams JM, Badger J, et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem. 2004;279:55827–55832.
   PubMed Web of Science ®Google Scholar
• Drube J, Ernst T, Pfirrmann M, et al. PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells. Oncotarget. 2018;9:9442–9455.
   PubMedGoogle Scholar
• Manic G, Obrist F, Kroemer G, et al. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1:e29911.
   PubMedGoogle Scholar
• Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4:151–175.
   PubMed Web of Science ®Google Scholar
• Joo JH, Dorsey FC, Joshi A, et al. Hsp90-Cdc37 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell. 2011;43:572–585.
   PubMed Web of Science ®Google Scholar
• Jiao H, Su GQ, Dong W, et al. Chaperone-like protein p32 regulates ULK1 stability and autophagy. Cell Death Differ. 2015;22:1812–1823.
   PubMed Web of Science ®Google Scholar
• Nazio F, Cecconi F. mTOR, AMBRA1, and autophagy: an intricate relationship. Cell Cycle. 2013;12:2524–2525.
   PubMed Web of Science ®Google Scholar
• Deng L, Wang C, Spencer E, et al. Activation of the I kappa B kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000;103:351–361.
   PubMed Web of Science ®Google Scholar
• Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514–2520.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054–1061.
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res. 2006;12:7374–7379.
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim D, Kim DW, et al. Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase dependent. Hematol Oncol. 2009;27:190–197.
   PubMed Web of Science ®Google Scholar
• Liu F, Shinomiya H, Kirikae T, et al. Characterization of murine grancalcin specifically expressed in leukocytes and its possible role in host defense against bacterial infection. Biosci Biotechnol Biochem. 2004;68:894–902.
   PubMed Web of Science ®Google Scholar
• Salomoni P, Calabretta B. Targeted therapies and autophagy: new insights from chronic myeloid leukemia. Autophagy. 2009;5:1050–1051.
   PubMed Web of Science ®Google Scholar
• Liu CC, Lin YC, Chen YH, et al. Cul3-KLHL20 ubiquitin ligase governs the turnover of ULK1 and VPS34 complexes to control autophagy termination. Mol Cell. 2016;61:84–97.
   PubMed Web of Science ®Google Scholar
• Flamant S, Ritchie W, Guilhot J, et al. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. Haematologica. 2010;95:1325.
   PubMed Web of Science ®Google Scholar
• San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, et al. MicroRNA expression profiling in Imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8:69.
   PubMed Web of Science ®Google Scholar
• Maubach G, Lim MCC, Chen J, et al. miRNA studies in in vitro and in vivo activated hepatic stellate cells. World J Gastroenterol. 2011;17:2748–2773.
   PubMed Web of Science ®Google Scholar
• Andreo U, Guo L, Chirieac DV, et al. Insulin-stimulated degradation of apolipoprotein B100: roles of class II phosphatidylinositol-3-kinase and autophagy. PLOS ONE. 2013;8:e57590.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1–222.
   PubMed Web of Science ®Google Scholar
• Lee JY, Koga H, Kawaguchi Y, et al. HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. Embo J. 2010;29:969–980.
   PubMed Web of Science ®Google Scholar